NT5E CpG island methylation is a favourable breast cancer biomarker
NT5E CpG island methylation is a favourable breast cancer biomarker
About this item
Full title
Author / Creator
Lo Nigro, C , Monteverde, M , Lee, S , Lattanzio, L , Vivenza, D , Comino, A , Syed, N , McHugh, A , Wang, H , Proby, C , Garrone, O , Merlano, M , Hatzimichael, E , Briasoulis, E , Gojis, O , Palmieri, C , Jordan, L , Quinlan, P , Thompson, A and Crook, T
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied
NT5E
(5′-nucleotidase, ecto) expression and
NT5E
CpG island methylation in breast cancer.
Methods:
We used RT–PCR, qPCR, methylation-specif...
Alternative Titles
Full title
NT5E CpG island methylation is a favourable breast cancer biomarker
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3389412
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3389412
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2012.212
